Cel-Sci
CVM
#9774
Rank
HK$0.39 B
Marketcap
HK$49.82
Share price
1.75%
Change (1 day)
-62.57%
Change (1 year)

P/E ratio for Cel-Sci (CVM)

P/E ratio as of December 2025 (TTM): -0.5660

According to Cel-Sci 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.566032. At the end of 2024 the company had a P/E ratio of -63.5.

P/E ratio history for Cel-Sci from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-63.523.67%
2023-51.4-56.82%
2022-119-67.67%
2021-368-18.35%
2020-45118.13%
2019-382458.29%
2018-68.3151.14%
2017-27.2-69.29%
2016-88.6117.84%
2015-40.7-23.69%
2014-53.3-64.46%
2013-1500%
2012-15072.97%
2011-86.7-116.76%
2010518-400.42%
2009-172-4.3%
2008-180-4.76%
2007-1891.61%
2006-186-46.09%
2005-345-14.81%
2004-405125%
2003-1801066.67%
2002-15.4-81.91%
2001-85.3

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Curis
CRIS
-0.3723-34.23%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
-150 26,415.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
25.5-4,606.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Xencor
XNCR
-9.94 1,656.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
44.9-8,036.04%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Johnson & Johnson
JNJ
19.4-3,522.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
8.44-1,591.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
-0.0167-97.05%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.